Please refer the enclosed intimation letter

0 Thyrocare Tests you can trust August 17, 2026 National Stock Exchange of India Limited BSE Limited Exchange Plaza Phiroze Jeejeebhoy Towers B(SaYnMdrBaO KLu:r TlaH CYoRmOpCleAxR, E ) D(SaClaRlI SPt rCeOeDt, E: 539871) B andra (E), Mumbai - 400051 Mumbai- 400001 Sub: Communication received from Docon Technologies Private Limited (‘Promoter’) regarding release of pledge over 7,94,69,696 Equity Shares of Thyrocare Technologies Limited (“Company”) Ref: Disclosure pursuant to Regulations 29(2), 31(2) and 31(3) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, as received from the Promoter Dear Sir/Madam, Docon Technologies Private Limited, Promoter of the Company We wish to inform you that the Company has received a communication from API Holdings Limited , inter alia informing that pursu7a,9nt4 t,6o 9th,6e9 f6u lel qreudietym sphtaiorne sand repayment of the Non-Convertible Debentures issued by , the ultimate holding company of the Company, the pledge created over of the Company held by the Promoter has been released. The Promoter has further informed that, following the aforesaid repayment, API Holdings Limited has no outstanding debt under the said Non-Convertible Debentures and the entire shareholding held by the Promoter in the Company is now free from pledge. In this regard the Promoter has submitted the requisite disclosures pursuant to Regulations 29(2), 31(2) and 31(3) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. A copy of the disclosure received from the Promoter is enclosed herewith for your information and taking the same on record. T hyrocare Technologies Limited, Y ours Faithfully, F or Brijesh Kumar Company Secretary and Compliance Officer Encl. A/a Thyrocare Technologies Limited 9 D-37 /1, TTC MIDC, Turbhe, Navi Mumbai-400 703, India (9 022-3090 0000 ~ enquiry@thyrocare.com (@www.thyrocare.com (CIN : L85110MH2000PLC123882) DOCON TECHNOLOGIES PRIVATE LIMITED August 17, 2026 To, To, National Stock Exchange of India Limited BSE Limited Exchange Plaza, C-1, Phiroze Jeejeebhoy Towers, Block G, Bandra Kurla Complex, Dalal Street, Mumbai-400001 Bandra (E), Mumbai - 400051 Thyrocare Technologies Limited D37 /3, TTC MIDC, Turbhe, Navi Mumbai - 400 073 Sub: Release of Pledge on 7,94,69,696 Equity Shares of Thyrocare Technologies Limited ("Thyrocare") Ref: Disclosures pursuant to Regulations 29(2), 31(2) and Regulation 31{3) of the Securities and Exchange Board of India {Substantial Acquisition of Shares and Takeovers) Regulations, 2011 Dear Sir & Madam, We refer to our earlier disclosures dated September 24, 2025, November 11, 2025, December 05, 2025, March 31, 2026, April 20, 2026 and August 13, 2026 made under Regulations 29(2) and 31 of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 ("SEBI SAST Regulations"), in relation to the encumbrance created by Docon Technologies Private Limited ("Docon"), Promoter of Thyrocare Technologies Limited (the "Company" /"Thyrocare"), pursuant to the Corporate Guarantee extended by Docon to secure the obligations of API Holdings Limited ("A PI"), the Holding Company, in respect of facilities availed by API through the issuance of unlisted, unrated, secured, redeemable, Non-Convertible Debentures ("NCDs"). In connection with the aforesaid NCDs, Docon had pledged its equity shares of Thyrocare in favour of Catalyst Trusteeship Limited, acting as the Debenture Trustee. The aforesaid NCDs, having an outstanding principal amount of INR 10,500 million, have been fully redeemed and repaid by API on August 14, 2026. Consequently, upon the full redemption and repayment of the aforesaid NCDs, the pledge created by Docon over the remaining 7,94,69,696 equity shares ofThyrocare in favour of Catalyst Trusteeship Limited, acting as the Debenture Trustee, has been fully released. Accordingly, as on August 17, 2026, the entire pledge created by Docon over its shareholding in equity shares of Thyrocare in connection with the aforesaid NCDs stands fully released. Further, there is no outstanding pledge or other encumbrance by the promoter over the share capital of Thyrocare. Pursuant to Regulations 29(2), 31(2) and 31(3) of the SEBI SAST Regulations, please find enclosed the requisite disclosures: 1. Disclosure under Regulation 29(2) of the SEBI {SAST) Regulations -Annexure I 2. Disclosure under Regulations 31(2) and 31(3) of the SEBI (SAST) Regulations -Annexure II You are requested to take the above disclosure on record. For Docon Tech~logies Private Limited Madhuri Sudhir Sarangdhar Company Secretary CIN No: U72900MH2016PTC443000 Registered Office: D37 /3, TIC Industrial Area, MIDC, Turbhe, Navi Mumbai, Thane, Maharashtra, India, 400705 Email Id: corporatesecretarial@docon.co.in I Telephone No.: 06364926900 DOCON TECHNOLOGIES PRIVATE LIMITED Annexure I Disclosures under Regulation 29(2) of Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 Name of the Target Company (TC) Thyrocare Technologies Limited ('Thyrocare") Name(s) of the acquirer and Persons Acting in Acquirer: #Docon Technologies Private Limited Concert (PAC) with the acquirer PAC: API Holdings Limited Whether the acquirer belongs to Yes Promoter/Promoter group Name(s) of the Stock Exchange(s) where the shares 1. BSE Limited ofTC a re Listed 2. National Stock Exchange of India Limited Details of the acquisition/ disposal as follows Number % w.r.t. total %w.r.t. share /voting total diluted capital wherever share/votin applicable(*) g capital of the TC(**) Before the acquisition under consideration, holding of: a. Shares carrying voting rights 17,30,304 1.09 1.08 b. Shares in the nature of encumbrance 7,94,69,696 49.93 49.79 (pledge/ lien/ non disposal undertaking/ c. Voting rights (VR) otherwise than by shares NIL NIL NIL d. Warrants/convertible securities/any other NIL NIL NIL instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) e. Total (a+b+c+d) 8,12,00,000 51.02 50.87 Details of acquisition/sale a. Shares carrying voting rights acquired/sold Nil Nil Nil b. VRs acquired /sold otherwise than by Nil Nil Nil shares C. Warrants/convertible securities/any other Nil Nil Nil d. instrument that entitles the acquirer to 7,94,69,696 49.93 49.79 receive shares carrying voting rights in the TC (speeify l:!olding in eael:! eategofV} acquired/sold Sl:!aFes eneumbeFed / in1.•oked/released b\• tl:!e aequiFeF) e. Total (a+b+c+/-d) 7,94,69,696 49.93 49.79 CIN No: U72900MH2016PTC443000 Registered Office: D37 /3, TIC Industrial Area, MIDC, Turbhe, Navi Mumbai, Thane, Maharashtra, India, 400705 Email Id: corporatesecretarial@docon.co.in I Telephone No.: 06364926900 DOCON TECHNOLOGIES PRIVATE LIMITED !After the acquisition/sale, holding of: a. Shares carrying voting rights 8,12,00,000 51.02 50.87 b. Shares encumbered with the acquirer Nil Nil Nil C. VRs otherwise than by shares Nil Nil Nil d. Warrants/convertible securities/any other Nil Nil Nil instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) after acquisition e. Total (a+b+c+d) 8,12,00,000 51.02 50.87 Mode of acquisition/ sale (e.g. open market/ off- Release of pledge over 7,94,69,696 equity shares of market/ public issue/ rights issue/ preferential trhyrocare Technologies Limited held by Docon allotment/ inter-se transfer etc). lfechnologies Private Limited (Promoter of lfhyrocare Technologies Limited), which had been pledged in favour of Catalyst Trusteeship Limited in connection with the Non-Convertible Debentures ("NCDs") issued by API Holdings Limited. Date of acquisition/ sale of shares/ VR or date of IAugust 17, 2026 (Release of Pledge) receipt of intimation of allotment of shares, whichever is applicable Equity share capital/ total voting capital of the TC 15,91,65,315 Equity shares having face [Showing first 8,000 characters — download PDF for full document]